PSRC Abstract Supplement BIA-ALCL. The terms "Breast Implant" and "Anaplastic Large Cell Lymphoma" were used as keywords and 'exploded' to include articles indexed with these headings as well as those indexed with any related terms. Inclusion criteria consisted of case reports or case series that describe BIA-ALCL. Articles published in English or French, commentaries or discussions, and studies on systemic ALCL were excluded. The data extracted included patient age, time of onset, diagnosis, pathophysiology, implant type, implant manufacturer, and treatment options.
CONCLUSION:
BIA-ALCL is a relatively new and rare condition that is not fully understood. This study reviews all the published BIA-ALCL cases and describes different characteristics associated with this condition. While further understanding of BIA-ALCL continues to be pursued, this review will aid in disseminating more information about this medical entity.
Predictors of Adverse Events Following Cleft Palate Repair in Nearly 5,000 Patients
Elbert J. Mets, BA, Fouad K. Chouairi, BS, Sina J. Torabi, BA, Michael Alperovich, MD Yale School of Medicine, New Haven, CT, USA PURPOSE: Cleft palate repair has rare, but potentially life-threatening risks. Understanding the risk factors for adverse events following cleft palate repair can guide surgeons in risk stratification and parental counseling. The present study seeks to characterize independent predictors of 30-day adverse events after primary cleft palate repair.
METHODS:
Using data from the National Surgical Quality Improvement Program Pediatric (NSQIP-P) database from 2012 to 2016, patients who underwent primary cleft palate repair were evaluated. All patients in the database were followed by specially-trained nurses for 30 postoperative days, regardless of discharge status. Patients experiencing any adverse event, reoperation, readmission, or wound dehiscence (palatal fistula) were identified. For each adverse event, patient demographics, comorbidities, and surgical variables were compared between patients who did and did not experience the adverse event. Separate multivariate logistic regression analyses were performed for each of the adverse events to identify independent predictors. Each regression controlled for demographics, as well as surgical variables and comorbidities that differed significantly between patients who experienced adverse events and the remaining cohort.
RESULTS:
4,989 patients who underwent primary cleft palate repair with complete data were identified. Patients had a mean age of 1.0 ± 0.3 years, and 53.5% were male. A total of 6.4% (320 patients) experienced any adverse event with 154 patients (3.1%) experiencing wound dehiscence. Thirty-day readmission and reoperation rates were 2.7% and 0.9%, respectively. On multivariate analysis, perioperative blood transfusion (adjusted odds ratio [aOR] 30.4, 95% confidence interval [CI] 7.4-124.6) and bronchopulmonary dysplasia/chronic lung disease (aOR 2.1, 95% CI 1.1-4.0) were significantly associated with any adverse PRS Global Open • 2019 event, as was longer hospital length of stay in days (aOR 1.1, 95% CI 1.0-1.1; HLOS). Similarly, perioperative blood transfusion (aOR 270.3, 95% CI 63.2-1,156.6), and cerebral palsy (aOR 10.5, 95% CI 1.9-59.1) were found to be significantly associated with reoperation, as was longer HLOS (aOR 1.1, 95% CI 1.0-1.2). ASA class IV (aOR 4.5, 95% CI 1.1-19.0), bronchopulmonary dysplasia/ chronic lung disease (aOR 2.4, 95% CI 1.1-5.2) and cerebral palsy (aOR 5.6, 95% CI 1.5-20.9) were significantly associated with readmission, as was HLOS (aOR 1.1, 95% CI 1.0-1.1). Perioperative blood transfusion (aOR 8.3, 95% CI 1.7-41.0) was significantly associated with wound dehiscence.
CONCLUSION:
Adverse events following cleft palate surgery are rare. Systemic disease remains the greatest predictor for readmission and reoperation, while intraoperative adverse events requiring blood transfusion predispose patients to post-surgical complications.
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INTRODUCTION:
Breast cancer (BC) research encompasses not only the study of tumor behavior, but also requires understanding the innumerable interactions that occur between breast cellular components and the extracellular matrix (ECM) in the development and progression of the disease. Despite extensive research, BC continues to be a leading cause of morbidity and mortality for women across the globe. The lack of three-dimensional models that are able to accurately replicate the tumor microenvironment and tumor-associated stroma has resulted in the unsuccessful translation of most preclinical studies into the clinic. It has been suggested that adipose tissue is a drugmetabolizing organ that protects tumor cells from chemotherapeutic agents. We have developed a tissue engineered, three-dimensional, high-throughput, patient specific, biomimetic model of BC that incorporates patient-derived adipocytes, adipose stromal cells, breast-duct organoids, and BC cells, and studied the effect of treatment with the chemotherapeutic agent doxorubicin on BC cell survival.
METHODS:
Under an approved IRB, breast tissue was acquired from patients and differentially processed to isolate mature adipocytes, stromal cells, and breast organoids which were subsequently co-cultured with cancer cells in a 0.6% type I collagen matrix. Mixtures containing fluorescently tagged MDA-MB-231 or MDA-MB-468 triple negative BC cells at a concentration of 200,000 cells/mL were plated onto 96 well plates. BC cells in plain collagen and biomimetic hydrogels without BC served as controls. Groups composed of three replicates of both Biomimetic and collagen only controls were treated with one time with serially diluted doses of doxorubicin at 0, 0.001, 0.01, 0.1, 1, and 10 uM, in cell culture media and fixed after 3 days in culture, stained, and fluorescently imaged using confocal microscopy. Tissues from three patients were used to test each cell line. Analysis was performed using Imaris™ software.
RESULTS:
After 3 days of doxorubicin treatment, MDA-MB-231 and MDA-MB-468 cell lines showed increased survival at 10mM doxorubicin (p<0.05) in the biomimetic platform derived from patient tissue, when compared to BC cells cultured in the collagen only controls. Moreover, fluorescent confocal microscopy demonstrated doxorubicin uptake by adipocytes that was directly proportional to increasing doxorubicin concentrations. No increased doxorubicin fluorescence was detected within the collagen-only controls.
CONCLUSION:
When cultured within a tissue engineered biomimetic platform comprised of patient tissue components, we observed significantly increased survival of two different triple negative breast cancer cell lines (MDA-MB-231 and MDA-MB-468) when compared to cultures in collagen alone. These data clearly demonstrate that the tumor microenvironment and neighboring tissue components modulates the effect of doxorubicin therapy on two different BC cell lines at least partially through adipocyte
